Optimized CXCR4-Targeting Peptide Pair for Cancer Imaging and Targeted Radionuclide Therapy
An optimized CXCR4-targeting peptide theranostic pair was developed for simultaneous PET imaging and therapeutic radionuclide delivery in CXCR4-expressing cancers.
Quick Facts
What This Study Found
Optimized CXCR4-targeting peptide theranostic pair: improved tumor uptake and imaging quality for diagnostic PET + therapeutic radionuclide delivery in CXCR4-expressing cancers.
Key Numbers
How They Did This
Peptide optimization for CXCR4 targeting, dual labeling for PET imaging and therapeutic radionuclide, biodistribution, and imaging studies.
Why This Research Matters
The same peptide that finds cancer on a scan can deliver radiation to kill it — precision therapy guided by precision diagnosis.
The Bigger Picture
Peptide-based theranostics are becoming standard for nuclear medicine cancer treatment, following the PRRT model success.
What This Study Doesn't Tell Us
Preclinical optimization. Clinical translation pathway needed.
Questions This Raises
- ?Which CXCR4+ cancers would benefit most from this theranostic?
- ?How does this compare to existing CXCR4-targeting agents (Pentixafor)?
- ?Would the therapeutic partner achieve sufficient tumor radiation doses?
Trust & Context
- Key Stat:
- Same peptide finds AND treats One peptide targets CXCR4 on cancer cells — labeled for imaging it finds tumors, labeled for therapy it irradiates them. Precision cancer medicine.
- Evidence Grade:
- Preclinical theranostic optimization.
- Study Age:
- Published in 2025.
- Original Title:
- Development of an Optimized CXCR4-Targeting Theranostic Pair.
- Published In:
- Journal of nuclear medicine : official publication, Society of Nuclear Medicine (2026)
- Authors:
- Kwon, Daniel, Bloise, Ingrid, Zhang, Zhengxing, Colpo, Nadine, Wilson, Ryan, Tan, Ruiyan, Merkens, Helen, Zeisler, Jutta, Lau, Joseph, Lin, Kuo-Shyan, Bénard, François
- Database ID:
- RPEP-15473
Evidence Hierarchy
Frequently Asked Questions
What is a theranostic?
A molecule that can both diagnose and treat disease. This CXCR4-targeting peptide finds cancer on PET scans and can deliver therapeutic radiation to the same tumors it identifies.
Which cancers express CXCR4?
Many — including certain blood cancers, breast cancer, lung cancer, and others. CXCR4 is a versatile target for peptide-based theranostics.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15473APA
Kwon, Daniel; Bloise, Ingrid; Zhang, Zhengxing; Colpo, Nadine; Wilson, Ryan; Tan, Ruiyan; Merkens, Helen; Zeisler, Jutta; Lau, Joseph; Lin, Kuo-Shyan; Bénard, François. (2026). Development of an Optimized CXCR4-Targeting Theranostic Pair.. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.269933
MLA
Kwon, Daniel, et al. "Development of an Optimized CXCR4-Targeting Theranostic Pair.." Journal of nuclear medicine : official publication, 2026. https://doi.org/10.2967/jnumed.125.269933
RethinkPeptides
RethinkPeptides Research Database. "Development of an Optimized CXCR4-Targeting Theranostic Pair..." RPEP-15473. Retrieved from https://rethinkpeptides.com/research/kwon-2026-development-of-an-optimized
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.